Belite Bio, Inc operates as a clinical stage biopharmaceutical drug development company. The Company focuses on developing novel therapeutics targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Belite Bio serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Belite Bio (BLTE US)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B5 | Prospectus

Notice of proposed sale of securities pursuant to Rule 144 (PDF)

Notice of proposed sale of securities pursuant to Rule 144 (PDF)

Notice of proposed sale of securities pursuant to Rule 144 (PDF)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)